Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1977 1
1979 1
1980 2
1981 2
1984 1
1987 2
1988 8
1989 2
1990 4
1991 2
1992 5
1993 4
1994 2
1995 6
1996 11
1997 8
1998 6
1999 14
2000 10
2001 7
2002 10
2003 12
2004 14
2005 12
2006 14
2007 25
2008 28
2009 29
2010 13
2011 32
2012 54
2013 42
2014 47
2015 34
2016 37
2017 31
2018 34
2019 44
2020 57
2021 74
2022 62
2023 58
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

785 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Rosenstock J, et al. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Lancet. 2021. PMID: 34186022 Clinical Trial.
Participants were randomly assigned (1:1:1:1) via computer-generated random sequence to once a week tirzepatide (5, 10, or 15 mg), or placebo. All participants, investigators, and the sponsor were masked to treatment assignment. The primary endpoint was the mean change in …
Participants were randomly assigned (1:1:1:1) via computer-generated random sequence to once a week tirzepatide (5, 10, or 15 mg), or placeb …
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
BACKGROUND: Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. ...All participants, investigators, and the sponsor were masked to treatment assignment. Coprimary endpoints were the percent change in bodyweight fro …
BACKGROUND: Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. ...All participan …
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.
Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R. Heymsfield SB, et al. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457. JAMA Netw Open. 2021. PMID: 33439265 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This double-masked, placebo-controlled, 48-week, phase 2 randomized clinical trial was conducted among adults with type 2 diabetes, body mass index between 28 and 40, and glycated hemoglobin (HbA1c) levels between 6.5% and 10.0% at …
DESIGN, SETTING, AND PARTICIPANTS: This double-masked, placebo-controlled, 48-week, phase 2 randomized clinical trial was conducted a …
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Inagaki N, et al. Lancet Diabetes Endocrinol. 2022 Sep;10(9):623-633. doi: 10.1016/S2213-8587(22)00188-7. Epub 2022 Jul 30. Lancet Diabetes Endocrinol. 2022. PMID: 35914543 Clinical Trial.
Participants were stratified based on baseline HbA(1c) (8.5% or >8.5%), baseline BMI (<25 or 25 kg/m(2)), and washout of antidiabetic medication. Participants, investigators, and the sponsor were masked to treatment assignment. The starting dose of tirzepatide was 2. …
Participants were stratified based on baseline HbA(1c) (8.5% or >8.5%), baseline BMI (<25 or 25 kg/m(2)), and washout of antidiabetic …
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Sorli C, et al. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.
Participants did their own injections and were encouraged to administer them on the same day of each week in the same area of their body; the time of day and proximity of meal times was not specified. ...Investigators, participants, and the funder of the study remai …
Participants did their own injections and were encouraged to administer them on the same day of each week in the same area of their …
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Lau DCW, et al. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016/S0140-6736(21)01751-7. Epub 2021 Nov 16. Lancet. 2021. PMID: 34798060 Clinical Trial.
Similar weight loss reductions were observed with the treatment policy estimand. ...The findings support the development of molecules with novel mechanisms of action for weight management. FUNDING: Novo Nordisk A/S....
Similar weight loss reductions were observed with the treatment policy estimand. ...The findings support the development of molecules …
Effects of Fecal Microbiome Transfer in Adolescents With Obesity: The Gut Bugs Randomized Controlled Trial.
Leong KSW, Jayasinghe TN, Wilson BC, Derraik JGB, Albert BB, Chiavaroli V, Svirskis DM, Beck KL, Conlon CA, Jiang Y, Schierding W, Vatanen T, Holland DJ, O'Sullivan JM, Cutfield WS. Leong KSW, et al. JAMA Netw Open. 2020 Dec 1;3(12):e2030415. doi: 10.1001/jamanetworkopen.2020.30415. JAMA Netw Open. 2020. PMID: 33346848 Free PMC article. Clinical Trial.
OBJECTIVE: To assess efficacy of fecal microbiome transfer (FMT) to treat adolescent obesity and improve metabolism. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-masked, placebo-controlled trial (October 2017-March 2019) with a 26-week follow-up was conducted …
OBJECTIVE: To assess efficacy of fecal microbiome transfer (FMT) to treat adolescent obesity and improve metabolism. DESIGN, SETTING, AND PA …
Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial.
Beardsall K, Thomson L, Guy C, Iglesias-Platas I, van Weissenbruch MM, Bond S, Allison A, Kim S, Petrou S, Pantaleo B, Hovorka R, Dunger D; REACT collaborative. Beardsall K, et al. Lancet Child Adolesc Health. 2021 Apr;5(4):265-273. doi: 10.1016/S2352-4642(20)30367-9. Epub 2021 Feb 10. Lancet Child Adolesc Health. 2021. PMID: 33577770 Free PMC article. Clinical Trial.
Infants were randomly assigned (1:1) to real-time CGM or standard care (with masked CGM for comparison) using a central web randomisation system, stratified by recruiting centre and gestational age (<26 or 26 weeks). ...
Infants were randomly assigned (1:1) to real-time CGM or standard care (with masked CGM for comparison) using a central web randomisa …
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM; Diabetes Prevention Program Research Group. Apolzan JW, et al. Ann Intern Med. 2019 May 21;170(10):682-690. doi: 10.7326/M18-1605. Epub 2019 Apr 23. Ann Intern Med. 2019. PMID: 31009939 Free PMC article. Clinical Trial.
BACKGROUND: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. OBJECTIVE: To identify some predictors of LTWL. ...RESULTS: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS gr …
BACKGROUND: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. OBJECTIV …
A trial of sugar-free or sugar-sweetened beverages and body weight in children.
de Ruyter JC, Olthof MR, Seidell JC, Katan MB. de Ruyter JC, et al. N Engl J Med. 2012 Oct 11;367(15):1397-406. doi: 10.1056/NEJMoa1203034. Epub 2012 Sep 21. N Engl J Med. 2012. PMID: 22998340 Free article. Clinical Trial.
However, data are lacking to show that the replacement of sugar-containing beverages with noncaloric beverages diminishes weight gain. METHODS: We conducted an 18-month trial involving 641 primarily normal-weight children from 4 years 10 months to 11 years 11 months …
However, data are lacking to show that the replacement of sugar-containing beverages with noncaloric beverages diminishes weight gain …
785 results